Baolingbao Biology Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Operating Revenue	2,814	2,751	2,392	2,516	2,713	2,755
Other Revenue	-	-	9.46	7.65	-	9.9
Revenue	2,814	2,751	2,402	2,524	2,713	2,765
Revenue Growth (YoY)	10.99%	14.54%	-4.84%	-6.96%	-1.89%	34.58%
Cost of Revenue	2,427	2,386	2,123	2,326	2,404	2,397
Gross Profit	386.83	364.72	278.47	197.52	308.4	368.24
Selling, General & Admin	168.62	156.42	106.05	106.5	129.8	122.17
Research & Development	20.8	13.78	9.54	11.3	8.46	12.58
Other Operating Expenses	-1.95	5.72	15.66	15.74	15.95	16.33
Operating Expenses	187.46	175.92	134.77	137.74	151.82	155.21
Operating Income	199.37	188.8	143.7	59.78	156.58	213.03
Interest Expense	-	-	-13.04	-22.68	-26.54	-16.95
Interest & Investment Income	1.96	1.96	6.9	7.36	7.97	18.85
Currency Exchange Gain (Loss)	-	-	6.64	1.61	12.17	-4.28
Other Non Operating Income (Expenses)	-16.08	-9.55	1.92	-3.09	-1.53	0.92
EBT Excluding Unusual Items	186.28	181.21	146.12	42.98	148.65	211.58
Gain (Loss) on Sale of Investments	-	-	-	-	2.61	11.23
Gain (Loss) on Sale of Assets	-	-	0.41	-0.05	-0.05	-
Asset Writedown	-3.35	-3.4	-22.56	0.01	-2.32	0.83
Other Unusual Items	-	-	7.15	22.17	7.79	13.09
Pretax Income	182.93	177.81	131.11	65.11	156.69	236.74
Income Tax Expense	28.52	27.18	19.95	11.15	23.52	35.16
Earnings From Continuing Operations	154.4	150.63	111.16	53.97	133.17	201.58
Net Income	154.4	150.63	111.16	53.97	133.17	201.58
Net Income to Common	154.4	150.63	111.16	53.97	133.17	201.58
Net Income Growth	11.61%	35.50%	105.97%	-59.47%	-33.94%	304.27%
Shares Outstanding (Basic)	374	367	371	360	370	373
Shares Outstanding (Diluted)	374	367	371	360	370	373
Shares Change (YoY)	2.80%	-0.85%	2.99%	-2.74%	-0.91%	4.81%
EPS (Basic)	0.41	0.41	0.30	0.15	0.36	0.54
EPS (Diluted)	0.41	0.41	0.30	0.15	0.36	0.54
EPS Growth	8.56%	36.67%	100.00%	-58.33%	-33.33%	285.71%
Free Cash Flow	56.63	70.07	58.79	130.05	-223.72	113.42
Free Cash Flow Per Share	0.15	0.19	0.16	0.36	-0.60	0.30
Dividend Per Share	-	-	0.095	0.080	0.080	0.060
Dividend Growth	-	-	18.75%	-	33.33%	-
Gross Margin	13.75%	13.26%	11.59%	7.83%	11.37%	13.32%
Operating Margin	7.08%	6.86%	5.98%	2.37%	5.77%	7.70%
Profit Margin	5.49%	5.47%	4.63%	2.14%	4.91%	7.29%
Free Cash Flow Margin	2.01%	2.55%	2.45%	5.15%	-8.25%	4.10%
EBITDA	317.87	307.23	261.84	177.62	258.01	318.01
EBITDA Margin	11.30%	11.17%	10.90%	7.04%	9.51%	11.50%
D&A For EBITDA	118.5	118.43	118.14	117.84	101.43	104.98
EBIT	199.37	188.8	143.7	59.78	156.58	213.03
EBIT Margin	7.08%	6.86%	5.98%	2.37%	5.77%	7.70%
Effective Tax Rate	15.59%	15.29%	15.22%	17.12%	15.01%	14.85%
Revenue as Reported	-	-	2,402	2,524	2,713	2,765
Advertising Expenses	-	-	1.87	2.62	2.64	1.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.